MarginsXMarginsX
Home › Markets › Health Care › LRMR

Larimar Therapeutics Inc. (LRMR)

LRMR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.00
-0.66% on the day
Market cap
$311.6M
Small cap
Revenue · 2019
$0
No prior year to compare
Net income · 2019
-$23.1M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2019-12-31, https://www.sec.gov/Archives/edgar/data/1374690/000156459020008984/0001564590-20-008984-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2019-12-31.

Profile

FieldValue
TickerLRMR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2014
SEC CIK0001374690
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2019

LineValue
Revenue$0
Net income-$23.1M
Operating income-$23.2M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$1.0M
Total assets$5.2M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
8.3 months
$92.7M cash at June 30, 2026
Share count, 1 year
+21.4%
2025-08-12 to 2026-08-02 · +140.0% over 3 years
Going-concern doubt
Yes
10-Q filed August 4, 2026
Insider net buying, 12 months
$25.7M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-08-04
Cash and burn$92.7M cash; operating cash flow -$33.6M a quarter.Report 2026-06-30
Shares outstanding103,882,937 (2026-08-02); 85,590,392 a year earlier; 43,277,500 three years earlier.Cover page 2026-08-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-02-26
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $25.7M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$32.8M-$44.0M$92.7MNo debt tagsNeeds four quarters10-Q 2026-08-04
Q1 2026
2026-03-31
Not filed-$29.6M-$44.6M$177.9MNo debt tagsNeeds four quarters10-Q 2026-08-04
Q4 2025
2025-12-31
Not filed-$62.5MNot filed$85.4MNo debt tagsNeeds four quarters10-K 2026-03-19
Q3 2025
2025-09-30
Not filed-$47.7MNot filed$90.1MNo debt tagsNeeds four quarters10-Q 2025-11-05
Q2 2025
2025-06-30
Not filed-$26.2M-$19.4M$20.6MNo debt tagsNeeds four quarters10-Q 2026-08-04
Q1 2025
2025-03-31
Not filed-$29.3M-$26.5M$21.1MNo debt tagsNeeds four quarters10-Q 2026-08-04
Q4 2024
2024-12-31
Not filed-$28.8M-$21.8M$33.2MNo debt tagsNeeds four quarters10-K 2026-03-19
Q3 2024
2024-09-30
Not filed-$15.5M-$24.5M$35.1MNo debt tagsNeeds four quarters10-Q 2025-11-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-02-26
Latest annual report10-K2026-03-19
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-11-16
Latest proxyDEF 14A2026-04-20

Source: SEC EDGAR submissions feed, 709 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+26.4%
1 month+39.8%
3 months-29.3%
Year to date-20.7%
1 year-8.2%
From 52-week high-49.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ENTAEnanta Pharmaceuticals Inc.$10.67-2.91%$310.8M
BNTCBenitec Biopharma Inc.$8.54-5.53%$308.5M
GALTGalectin Therapeutics Inc.$3.02-0.98%$305.2M
ALTAltimmune Inc.$1.56-5.17%$303.6M
EBSEmergent BioSolutions Inc.$5.81+0.35%$298.7M
EVMNEvommune Inc.$7.10-6.95%$293.6M
AVIRAtea Pharmaceuticals Inc.$4.12-4.19%$330.9M
FULCFulcrum Therapeutics Inc.$3.71-1.59%$283.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier